Loading company…
Unicet develops cell-based immune therapies for cancer, infectious diseases, and autoimmune diseases.
Unicet develops immune cell drugs based on ?d T cells and studies ?d T cell/BTN immune mechanisms for cancer, infectious diseases, and autoimmune diseases. Founded in 2018, the company is based in Beijing, China. In June 2026, it raised nearly CNY 200 million in Series A funding from Shenzhen Capital Real Estate Fund, Shunxi Fund, Zhongguancun Development Venture, Lapam Capital, and Flyfot Ventures. The funding is intended to support clinical research and development of its technology platform.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in